Database D-RSC has created an integrated database of patient-level data collected in DMD clinical trials
The database currently contains 14 clinical datasets ( Table 1) that may be made available to the broader community to the extent permitted by the owners of each contributing dataset. Data exceeds HIPAA "Safe Harbor" standards and is mapped to CDISC standards, making it ready for regulatory submissions.
Proposed Context of Use for Platform
General Description: A disease progression model-based CTS tool designed to optimize clinical trial enrichment and design of studies to investigate efficacy of potential therapies for DMD. Measurements of DMD disease progression will be based on changes in a series of endpoints -velocities of completion of the supine-stand test, 4-stair climb test, 10-meter walk/run test and 30-foot walk/run test, forced vital capacity, North Star Ambulatory Assessment and the transition between scores in the Brooke scale.
Target Population for Use: Individuals with DMD 4 years or older (endpoint-dependent) regardless of stage of disease.
Stage of Drug Development for Use:
All clinical efficacy evaluation stages of drug development in DMD, including early efficacy, proof-of-concept, dose-ranging, and registration studies.
Intended Application: To help inform, through simulations, the definition of inclusion/exclusion criteria, enrichment strategies, stratification approaches, timing and selection of clinical assessments, trial duration and sample size for studies evaluating therapeutic candidates for DMD. Jane Larkindale 1 , Daniela J Conrado 1 , Alexander K Berg 1 , Diane Corey 1 , Klaus Romero 1 , on behalf of the Duchenne Regulatory Science Consortium (D-RSC)* and the CINRG DNHS investigators. 1 Critical Path Institute (C-Path), Tucson, AZ The Duchenne Regulatory Science Consortium (D-RSC) at the Critical Path Institute was set up to develop tools to accelerate therapy development for Duchenne muscular dystrophy (DMD). D-RSC will provide the Duchenne drug development ecosystem with:
o A CDISC (Clinical Data Interchange Standards Consortium) standard for Duchenne, which defines the regulatory-acceptable format, structure and terminology used in databases from clinical studies, enabling comparison between datasets. Available at https://www.cdisc.org/standards/therapeutic-areas/duchenne-muscular-dystrophy/duchenne-musculardystrophy-therapeutic-area. o An integrated database bringing together disease natural history data from multiple sources using the standard -available for analysis by the community to the extent permitted by the owners of each dataset. [Currently includes 14 datasets, 7 can be shared] o Clinical trial simulation tool developed from mathematical models of disease progression for submission to the regulatory authorities as a fit-for-purpose tool -which will be available to the community when qualified; potentially other regulatory-endorsed drug development tools. The Critical Path Institute is a non-profit organization that specializes in forming public-private partnerships to develop drug development tools, and work towards qualification/endorsement of such tools with the regulatory authorities (e.g. FDA, EMA). Each consortium is advised by an FDA liaison to ensure that products of the consortia are suitable for qualification Graphs show the relationship between the measurement predicted by the quadratic function correspond to actual observations. Deviation from the predicted velocity showing that these models have reasonable predictive value. However, we will test more complex model forms before selecting the best model for each endpoint. Walk/Run
